Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Damora Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Damora Therapeutics, Inc.’s stock price such as:

• Damora Therapeutics, Inc.’s current stock price and volume
• Why Damora Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for DMRA from analysts
• DMRA’s stock price momentum as measured by its relative strength

About Damora Therapeutics, Inc. (DMRA)

Before we jump into Damora Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Want to learn more about Damora Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Damora Therapeutics, Inc..

Damora Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Damora Therapeutics, Inc.’s stock price was $28.990.

Damora Therapeutics, Inc. is down 0.75% from its previous closing price of $29.210.

During the last market session, Damora Therapeutics, Inc.’s stock traded between $28.650 and $30.270. Currently, there are approximately 34.30 million shares outstanding for Damora Therapeutics, Inc..

Damora Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Damora Therapeutics, Inc. Stock Price History

Damora Therapeutics, Inc.’s (DMRA) price is currently up 11.46% so far this month.

During the month of July, Damora Therapeutics, Inc.’s stock price has reached a high of $34.890 and a low of $25.760.

Over the last year, Damora Therapeutics, Inc. has hit prices as high as $38.325 and as low as $2.450.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Damora Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 2 analysts who downgraded Damora Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Damora Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Damora Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Damora Therapeutics, Inc. (DMRA) by visiting AAII Stock Evaluator.

Relative Price Strength of Damora Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Damora Therapeutics, Inc. has a weighted four-quarter relative price strength of 73.12%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how Damora Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Damora Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Damora Therapeutics, Inc.’s stock price is $28.990, which is down 0.75% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Damora Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.